Comparison of the Effects of Apixaban on Thrombin Generation in Patients With de Novo Multiple Myeloma
Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE SAINT ETIENNE · Jun 19, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, called APIXABOR, is studying how the medication Apixaban affects blood clotting in patients with multiple myeloma (a type of blood cancer) compared to patients undergoing total knee replacement surgery. People with multiple myeloma are at a higher risk of developing blood clots, so it's important to find the best ways to prevent this. The study will look at how Apixaban works differently in these two groups of patients and whether it can help manage their risk of blood clots more effectively.
To participate in this trial, you must be at least 18 years old and either have a new diagnosis of multiple myeloma requiring Apixaban to prevent blood clots or be scheduled for knee replacement surgery with the same treatment. Participants will be asked to sign an informed consent form and will be monitored for how well the medication works in their bodies. It’s important to note that certain individuals, such as those who are pregnant or have specific health conditions that prevent them from taking Apixaban, will not be eligible for this study. This research could provide valuable information on improving care for patients with multiple myeloma and help doctors better manage blood clot risks in these patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years old,
- • Signed informed consent,
- • Patient covered by a social security scheme.
- • Group 1 : patient with a diagnosis of de novo multiple myeloma, with an indication of thromboprophylaxis with Apixaban,
- • Group 2 : patient requiring a surgery for total knee replacement, , with an indication of thromboprophylaxis with Apixaban.
- Exclusion Criteria:
- • Curative doses of anticoagulation treatment,
- • Contra-indication to Apixaban,
- • Pregnant or breastfeeding woman,
- • Refusal to sign consent,
- • Patient under legal protection.
About Centre Hospitalier Universitaire De Saint Etienne
The Centre Hospitalier Universitaire (CHU) de Saint-Étienne is a leading academic medical center in France, dedicated to advancing healthcare through innovative clinical research and high-quality patient care. With a robust infrastructure that supports a wide range of medical specialties, CHU de Saint-Étienne fosters collaboration between healthcare professionals, researchers, and academic institutions. The center is committed to conducting rigorous clinical trials that adhere to ethical standards and regulatory requirements, aiming to improve treatment outcomes and enhance the overall health of the community. Through its dedication to scientific excellence and patient-centered care, CHU de Saint-Étienne plays a pivotal role in the advancement of medical knowledge and the development of new therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Saint étienne, , France
Patients applied
Trial Officials
Emilie CHALAYER, MD
Principal Investigator
CHU de Saint-Etienne
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported